Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Revenue growth | — | 58.5% | 16.5% | 41.6% | 34.5% | -43.0% | 57.7% | -30.4% | 59.6% | 16.9% |
| Operating income | -$32.2M | -$69.6M | -$90.9M | -$106M | -$137M | -$268M | -$458M | -$515M | -$534M | -$441M |
| Operating margin | -195.2% | -266.3% | -298.6% | -246.8% | -235.5% | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Net income | -$31.6M | -$67.5M | -$85.3M | -$474M | -$134M | -$268M | -$474M | -$481M | -$519M | -$413M |
| Net margin | -192.0% | -258.6% | -280.4% | -1100.1% | -231.5% | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (diluted) | -$1.42 | -$1.88 | -$1.98 | -$2.11 | -$2.40 | -$3.78 | -$6.16 | -$5.42 | -$5.25 | -$3.81 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $36.1M | -$65.3M | -$61.3M | -$103M | -$49.9M | -$225M | -$333M | -$394M | -$349M | -$395M |
| Capital expenditures | $6.17M | $10.1M | $6.36M | $6.79M | $3.58M | $12.8M | $13.6M | $14.0M | $5.78M | $1.13M |
| Free cash flow | $29.9M | -$75.4M | -$67.6M | -$110M | -$53.5M | -$238M | -$347M | -$408M | -$355M | -$396M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $273M | $341M | $58.9M | $57.2M | $160M | $123M | $524M | $227M | $189M | $155M |
| Total assets | $299M | $376M | $347M | $334M | $676M | $1.29B | $1.52B | $1.30B | $1.19B | $842M |
| Total liabilities | — | — | — | — | — | — | $285M | $251M | $319M | $171M |
| Shareholders' equity | $210M | $301M | $278M | $270M | $527M | $1.04B | $1.24B | $1.05B | $872M | $671M |
| Retained earnings | -$53.6M | -$121M | -$201M | -$301M | -$435M | -$703M | -$1.18B | -$1.66B | -$2.18B | -$2.59B |
| Shares (wtd avg diluted) | 36.0M | 42.4M | 45.2M | 50.2M | 56.0M | 70.9M | 77.0M | 88.8M | 98.8M | 108M |
Every figure is extracted from Intellia Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.